September 7th 2024
Catch up on the top radiology content of the past week.
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Satellite Symposia at the Annual Radiation Oncology Meeting
September 28-29, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
PSMA PET vs. Gallium-Based PET: Navigating NCCN Guidelines in Prostate Cancer Imaging
September 4th 2024Jaideep Sohi, MD, and Jeremie Calais, MD, examine the comparative merits of PSMA PET and Gallium-Based PET while exploring the application of NCCN Guidelines in prostate cancer imaging protocols.
FDA Clears Updated AI Software for MRI Neuroimaging
Offering enhanced deep learning technology, the updated NeuroQuant 5.0 software reportedly bolsters segmentation capabilities for amyloid-related imaging abnormalities (ARIA) in patients with Alzheimer’s disease.
Diffusion-Weighted MRI and Neoadjuvant Chemotherapy for Rectal Cancer: What New Research Reveals
In a comparison of imaging assessments to gauge the effectiveness of neoadjuvant chemotherapy for rectal adenocarcinoma, researchers found the combination of diffusion-weighted imaging and MR tumor regression grading had a 90 percent area under the curve (AUC) and a negative predictive value (NPV) of 93 percent.
FDA Expands Clearance of MRI-Guided AI Platform for Deep Brain Stimulation and Lesioning Techniques
Utilizing a new machine learning model, the OptimMRI software may improve radiosurgery applications and lesioning techniques such as MRI-guided focused ultrasound through enhanced targeting of the inferolateral part of the ventral intermediate nucleus (VIM).
Mammography Study: Can Stand-Alone AI Enhance Detection of Interval Breast Cancer?
Identifying over 23 percent of interval breast cancers with a 96 percent sensitivity in mammography interpretation, an emerging AI software also facilitated correct localization in over 75 percent of cases involving interval breast cancer, according to new research.